Latest From Gynesonics Inc.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced July through August 2015.
Diagnostic Imaging Equipment & Supplies
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Gynecological, Urological
- North America
- Parent & Subsidiaries
- Gynesonics Inc.
- Senior Management
Christopher M Owens, Pres. & CEO
David Toub, MD, Medical Dir.
Michael Munrow, VP, R&D
Jordan Bajor, COO
- Contact Info
Phone: (650) 216-3860
604 5th Ave.
Redwood City, CA 94063
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.